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Abstract
CRISPR tools can generate knockout and knock-in animal models easily, but the models
can contain off-target genomic lesions or random insertions of donor DNAs. Simpler
methods to identify off-target lesions and random insertions, using tail or earpiece
DNA, are unavailable. We develop CRISPR-KRISPR (CRISPR-Knock-ins and Random
Inserts Searching PRotocol), a method to identify both off-target lesions and random
insertions. CRISPR-KRISPR uses as little as 3.4 μg of genomic DNA; thus, it can be easily
incorporated as an additional step to genotype founder animals for further breeding.
Keywords: CRISPR, CIRCLE-seq, Off target, Knock-in, Random insertion, CRISPR-KRISPR,
Donor DNA, Intronic region, Repeat element

Background
Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein (Cas) nucleases that create double-stranded breaks (DSBs) at the
desired loci have been widely used as tools for generating genome-edited animal
models [1, 2]. Introduced DSBs are repaired with one of the following two mechanisms: (a) non-homologues end joining (NHEJ) and (b) homology-directed repair
(HDR). The insertion and deletion (indel) mutations can be introduced into the target region via the NHEJ system, whereas foreign DNA sequences can be inserted into
the target locus (knock-in) via the HDR mechanism [3, 4]. NHEJ is generally more
efficient than HDR, but knock-in of foreign DNA sequences is of wide interest to
the scientific community. For creating knock-in models, a few strategies using either
microinjection of long single-stranded DNA (lssDNA) [5] or double-stranded DNA
(dsDNA) cassettes as donors have been developed during the past 3–5 years, termed
Easi-CRISPR [6], Combi-CRISPR [7], 2C-HR CRISPR [8], and SPRINT-CRISPR [9],
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or by in vitro electroporation [10] or in vivo electroporation termed GONAD [11,
12] and i-GONAD [13, 14].
CRISPR genome editing technology has two drawbacks: off-target (OT) cleavages
and random insertion (RI) of the donor DNA molecules used for creating knockin alleles. OT cleavage and RI events are generally rare in mouse models created
using CRISPR methods. Even if such unwanted lesions exist in the genome, they can
be easily segregated. However, there are no simpler methods to identify OT and RI
events. With regards to identifying OT events, it is difficult to distinguish them from
de novo mutations [15, 16]. Eliminating OT mutations in CRISPR-based genome
editing is still challenging [17]. Various methods have been developed to detect OT
cleavage sites. They fall into two broad approaches: (1) in silico biased methods and
(2) in vivo/in vitro unbiased methods. In silico-based approaches include alignmentbased approaches such as Cas-Offinder [18] and scoring-based approaches such as
CHOPCHOP [19]. Examples of in vivo unbiased approaches include GUIDE-seq
[20] and DISCOVER-seq [21]. These cell-based genome-wide assays are thought to
identify OT effects with better precision because they rely on the use of endogenous
DNA repair mechanisms. In vitro unbiased approaches include SITE-Seq [22], Digenome-seq [23], and CIRCLE-seq [24]. These biochemical assays allow the detection
and quantification of OT effects by in vitro cleavage of naked genomic DNA with
Cas9-gRNA ribonucleoprotein (RNP). Among them, CIRCLE-seq is considered as
the most sensitive method for detecting OT sites, which relies on cleaving the circularized DNA with RNP and sequencing the flanking sequence of the cleaved site
[25]. In addition, verification of in vivo OTs (VIVO) is a method that combines CIRCLE-seq and target amplicon sequencing to effectively evaluate in vivo OT effects
[26].
In addition to OT cleavage, insertion of donor DNA at non-target genomic sites
is also a concern among genome edited animals. RIs of both dsDNA and lssDNA
donors, including their imprecise insertions at on-target sites, have been reported
[27, 28]. Characteristics of RI sites and how RIs occur are not well understood.
Another commonly encountered problem with the CRISPR animal genome-engineering method is that it would be practically impossible to breed each of the founders to
establish separate lines, especially if there are many founder animals containing the
desired on target edits. In such scenarios, it would be ideal to screen the founders for
unwanted genomic lesions and exclude the ones containing those for breeding and
narrowing down to a few founders that do not contain any OT cleavages or RIs.
In this report, we modified the CIRCLE-seq method, which was originally developed for OT cleavages, and developed a method called CRISPR-KRISPR that can
identify OT as well as RI events among the mouse models generated using the
CRISPR approach (see Fig. 1 for a schematic comparing the CIRCLE-seq and the
CRISPR-KRISPR methods). For testing the utility of the CRISPR-KRISPR method, we
chose to analyze the entire set of founder mice generated as part of a microinjectionbased knock-in experiment to insert a T2A-mCitrine cassette at the mouse Mmp9
locus [6, 29], with the goal of identifying, and ruling out, OT cleavages and RI events
and characterizing them.
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Fig. 1 Overview of CIRCLE-seq and CRISPR-KRISPR. Schematic of CIRCLE-seq (left) and CRISPR-KRISPR (right)
procedures. The CIRCLE-seq method can identify OT candidate sites (OCSs), whereas CRISPR-KRISPR can
identify both OCSs and insertion candidate sites (ICSs)

Results
Modification of the CIRCLE-seq method

We followed the steps to generate circularized DNA, as described in the original CIRCLE-seq method protocol, to obtain 250 ng circularized DNA library [24], but we could
only get 12 ng circularized DNA library. This amount of library DNA was not sufficient
for downstream processing. We then changed the fragmentation step from sonication
(i.e., physical DNA cleavage used in the original CIRCLE-seq protocol) to enzymatic
fragmentation to prepare the library (Fig. 1). With this modification, we were able to
obtain the required amount of circularized DNA library (>250 ng) from as little as 3.4 μg
of gDNA, whereas the original protocol required as much as 25 μg of gDNA (about 7.4
times more). The circularized DNA yield was over 150-fold higher in enzymatic digestion (our modified method) compared to the sonication process used in the original
CIRCLE-seq method.

Modifying the CIRCLE-seq method to identify OT and RI events

Our initial goal was to develop a method to identify OT among the entire set of mice
born in a knock-in mouse generation project by using the tail DNA samples. During the
process of modifying the CIRCLE-seq method (to identify OT sites), we realized the
potential of this method also to identify RIs, by strategically designing the guide RNAs
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(gRNAs) used in the assay: one gRNA binding to one of the arms and the second one
binding to an overlapping region between the insert and the second homology arm. We
named this strategy CRISPR-KRISPR (CRISPR- Knock-ins and Random Inserts Searching PRotocol)]. One single method (rather than two) to identify both OT and RI would
help in identifying the best founder(s), especially if there are many founders containing
the targeted insertion of the knock-in cassette.

A test project to validate the CRISPR-KRISPR method

One of the previously generated knock-in mouse projects (where we inserted a T2AmCitrine cassette into the Mmp9 locus [6] (Additional file 1: Fig. S1A)) met this criterion
because 67% (8/12) of the founder mice contained the targeted allele, and we wanted to
analyze all correctly targeted ones to rule out RIs before choosing the right founder(s)
for establishing the knock-in mouse line and to analyze all mice (including non-targeted
ones) to comprehensively investigate OTs. Based on the tail DNA genotyping assays
using two junction PCRs (one each on 5′ and 3′ junctions), we had identified eight correctly targeted (founders 1, 3, 4, 6, 7, 8, 11, and 12), three untargeted (founders 2, 5, and
9), and two imprecise/partial insertion alleles (founders 4 and 10) (Additional file 1: Fig.
S1B). Note that among the correctly targeted animals, one mouse (founder 4) also contained a mosaic imprecise/partial insertion allele [6]). For the CRISPR-KRISPR analysis,
we could not include founder 12 (one of the correctly targeted mice) because this mouse
died before weaning, and enough genomic DNA was not available. We sequenced the
targeted region of the three non-targeted founders (2, 5, and 9) to check if they contained indels and found that they all had indels (data not shown). This suggested that the
genome editing efficiency of the gRNA (Mmp9-Cr1) used for knocking in of mCitrine
at the Mmp9 locus was 100%; thus, this set of 11 mice was a good set for OT and RI
analyses.

Identification (or ruling out) of OT sites using the CRISPR-KRISPR method

To investigate whether OT mutations were caused in zygote genome editing using
Mmp9-Cr1 gRNA (Fig. 1 and Additional file 1: Table S1), and to identify the OT candidate sites (OCSs) (Fig. 2A), we employed the CRISPR-KRISPR method and an in silico
method (Cas-OFFinder). The NGS sequencing of the CRISPR-KRISPR library identified
802 potential SpCas9 nuclease cleavage sites. The highest number of read counts was
found at the on-target site of Mmp9-Cr1 (2,088 reads of 36,858 CRISPR-KRISPR identified reads) (Fig. 2B, C). In addition, the consensus sequence analysis of 802 potential
cleavage sites showed a 100% match with the target sequence of Mmp9-Cr1 (5′-AAG
AAGGAGCCCTAGTTCAAGGG-3′), as expected. Furthermore, it had the canonical
PAM sequence of SpCas9 (5′-NGG-3′) (Fig. 2D).
Simultaneously, we used Cas-OFFinder method to predict sequence homology-based
potential OT sites, which showed 862,287 and 1,006,577 potential OT sites, with canonical 5′-NGG-3′ PAM and non-canonical PAM sequences, respectively (Additional file 1:
Table S2). Of note, the Cas-OFFinder list included all of the 802 potential cleavage sites
identified by CRISPR-KRISPR method (Fig. 2E).
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Fig. 2 Assessment of in vivo OT indels introduced with Mmp9-Cr1 gRNA. A Schematic illustrating OT
candidate sites (OCSs) identification and their confirmation procedure. OCSs for Mmp9-Cr1 gRNA were
identified by CRISPR-KRISPR and by Cas-OFFinder. The fragments containing OCSs selected were PCR
amplified from founder and wildtype (WT) mice. Amplicon sequencing of these fragments were performed
using a high-throughput sequencer. B Manhattan plot of 802 cleavage sites detected by CRISPR-KRISPR.
The length of bars represents CRISPR-KRISPR read count. The Mmp9-Cr1 on-target site is indicated in red.
Top 47 OCSs are indicated in blue. C The top 47 OCSs detected by CRISPR-KRISPR and three predicted
OCSs by Cas-OFFinder are shown. D Sequence logo of cleavage sites detected by CRISPR-KRISPR. E Venn
diagram showing the number of OCSs and overlap between those OCSs predicted by Cas-OFFinder and
CRISPR-KRISPR

These results suggest that the CRISPR-KRISPR method can reliably identify potential
OT sites.
Evaluation of OCSs by in vitro digestion

Next, we examined whether the potential OT sites will get cleaved by Cas9 using an
in vitro digestion method. For this, we chose a total of 50 sites: the list contained the top
47 (of the 802) sites identified from the CRISPR-KRISPR approach (i.e., the ones that
had highest read counts), and the remaining three sites were predicted by in silico analysis (these sites had three or fewer mismatches) (Fig. 2C). We designed PCR primer sets
(Additional file 1: Table S3) to amplify using the wildtype genome as a template, followed
by Cas9 treatment of the PCR fragments using Mmp9-Cr1 gRNA. Cas9 nuclease cleaved
7 of the 50 sites (OCS#001, OCS#011, OCS#017, OCS#022, OCS#025, OCS#028, and
OCS#037) (Fig. S2). The cleavage efficiency of on-target sites was 94.7%, and those of
OCSs (7 sites) ranged from 13.7 to 70.9%. All of the cleaved OCSs had canonical PAMs.
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Fig. 3 Validation of in vivo OT indels using targeted deep amplicon sequencing. A Targeted deep amplicon
sequencing for OCSs. Violin plots show the distribution of the number of reads for each OCS (top 47
OCSs detected by CRISPR-KRISPR (OCS001~OCS0047) and three uniquely predicted sites by Cas-OFFinder
(OCS802~OCS804)). Median distributions are shown by dark grey dots and lines, respectively. The dashed line
indicates required minimum number of reads (2,000 reads). B Validation of 50 OCSs in 11 founder mice and
three wildtype (WT) mice

Validation of OT mutations by targeted amplicon sequencing

To confirm whether the Mmp9 reporter founder mice carried OT mutations in these 50
OCSs, we performed targeted amplicon sequencing of all the 11 founder mice (Fig. 3A).
The results showed that the maximum frequency of indel mutations detected was less
than 0.2%, and these mutations were detected in amplicons of both F0 and wildtype
mice. If the mutation is introduced by four-cell stage, the frequency of detection of the
mutant allele is expected to be ~12.5%. However, no indel mutations exceeded this rate
(Fig. 3B). In vivo OT mutations were also undetected in the seven sites where cleavage
was confirmed by in vitro digestion. Thus, we conclude that Mmp9-Cr1 gRNA did not
cause OT mutations at 50 OCSs above a detection limit of approximately 0.1%.
Leveraging the CRISPR-KRISPR method to identify RI sites

In our previous knock-in reporter mouse model generation experiment (Mmp9-T2AmCitrine) [6], we noted one of the untargeted founders contained randomly inserted
donor DNA. Founder mouse 9 was negative for 5′ and 3′ junction PCRs, but the internal
primers (that bind only to the donor DNA sequence) amplified an expected sized band
(Additional file 1: Fig. S1B and S1C). This suggested that the T2A-mCitrine cassette may
have gotten inserted at a random genomic region (see founder 9 in Additional file 1: Fig.
S1C). In order to assess additional RI events among the entire panel of founders, we
estimated the donor copy number in each founder mouse by qPCR analysis using internal primers (that bind to the insertion cassette T2A-mCitrine). This assay is expected
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to show either a value of 1 (mono-allelic or heterozygous insertion) or 2 (bi-allelic or
homozygous insertion), assuming no mosaicism. If the value is more than 2, it suggests
that the founder animal may contain additional insertions (elsewhere in the genome).
Note that a value of 2 may also indicate one correctly targeted allele (heterozygous) and
another random insertion. The results showed that founder 7 contained more than three
copies (Additional file 1: Fig. S1D), suggesting that this mouse may also have RI (or multiple copies are inserted on target in a tandemly connected manner). We then set out to
systematically analyze RIs among all of the 11 founder mice using the CRISPR-KRISPR
method.
The strategy we employed is as follows. We designed two gRNAs—gRNA-L and
gRNA-R—to use them in the CRISPR-KRISPR assay. The gRNA-L binds to the left
arm whereas the gRNA-R binds an overlapping region of the right arm and the insertion cassette (Additional file 1: Fig. S3A and Table S1). CRISPR-KRISPR libraries derived
from pooled genomic DNA from all 11 founder mice (including genomic DNA from
a wildtype mouse as a separate sample) were treated with a respective gRNA, and the
regions cleaved by Cas9 were sequenced by next-generation sequencing (NGS) to identify insertion candidate sites (ICSs) (Additional file 1: Fig. S3B). As a result, 8 and 47
cleavage sites were detected for gRNA-L and gRNA-R, respectively. These cleavage sites
were confirmed by the Integrative Genomics Viewer (IGV), which revealed 26 ICSs
(Table 1). Among these, ICS#1, ICS#2, and ICS#21 were thought to be derived from
the on-target region (Table 1). Based on these analyses, we identified a total of 23 ICSs
(Table 1). Intriguingly, 17 out of 23 ICSs were detected in protein-coding genes (mostly
in introns). Of note, none of those 23 ICSs were located at the potential OCSs described
above (Additional file 1: Fig. S4).

Attributing different ICSs, which were identified by CRISPR-KRISPR analysis of the pooled
genomic samples, to specific founders of the panel

The CRISPR-KRISPR analysis was performed using the pooled DNA samples from all
of the 11 mice generated in a microinjection experiment. To experimentally verify the
ICSs, and to identify which ICSs corresponded to which founders, we designed PCR
primers (ICS primers) for all the ICSs (note that we designed 22 primer sets for 23 ISCs)
(Additional file 1: Table S4); ICS#3 and ICS#14 were considered to be derived from the
same ICS based on the mapped sequence (Additional file 1: Fig. S5). PCR was performed
using pooled gDNA containing equimolar amounts of gDNA from 11 founder mice and
a wildtype mouse as templates to verify the presence of the insertion cassette (Fig. 4A).
Amplification of PCR fragments was detected at 8 out of 22 sites (Fig. 4B). Next, to identify founder individuals with RI sequences, PCR was performed for each mouse for these
eight independent sites. The results showed that PCR amplification detected the eight
sites in 5 of the 11 F0 mice (founders 1, 6, 7, 9, and 11) (Fig. 4C). None of the insertions
were the same among different founder mice.
The insertion positions of all the eight sites were identified and confirmed by Sanger
sequencing. ICS#3/#14 were identical, and the mCitrine cassette was inserted into the
CA repeat sequence of the Kynu intronic region, accompanied by a 62 bp gap. In ICS#4,
the mCitrine cassette was inserted at the on-target site with an approximately 4 kb deletion. ICS#5/#9 was also an identical ICS, with the insertion of an mCitrine cassette
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Table 1 Summary of ICS detected by CRISPR-KRISPR
Insertion
candidate
sites (ICS)

gRNA used No. of reads Founder Chromosome
mouse

Start

End

#1

right

1820

-

2

164954903 164955063 Mmp9 on
target

#2

left

1680

-

2

164954709 164955052 Mmp9 on
target

#3

right

269

6

2

43676988

#4

right

158

1

2

164958347 164958445 Intergenic
region

#5

right

74

7

2

27945902

27946004

Col5a1
intronic region

#6

right

51

-

10

8621100

8621200

Cnnm2
intronic region

#7

left

48

9

9

63264772

63264909

Map2k5
intronic region

#8

right

43

-

6

91473078

91473209

Chchd4
intronic region

#9

left

42

7

2

27947501

27947631

Col5a1
intronic region

#10

right

40

11

2

164951625 164951696 Mmp9 intronic
region

#11

right

30

-

11

44994980

#12

left

25

-

12

118243649 118243801 Sp4 intronic
region

#13

right

23

-

15

86334151

86334255

Tbc1d22a
intronic region

#14

left

23

6

2

43677155

43677290

Kynu intronic
region

#15

right

21

11

2

164951440 164951518 Mmp9 intronic
region

#16

right

20

-

17

10769843

10769900

Pacrg intronic
region

#17

right

20

-

17

61954898

61955001

Intergenic
region

#18

right

15

-

10

107374530 107374593 Lin7a intronic
region

#19

left

15

-

6

38606367

38606454

Luc7l2 exonic/
intronic region

#20

right

12

-

18

43026996

43027098

Ppp2r2b
intronic region

#21

right

10

-

2

164954849 164954903 Mmp9 on
target

#22

right

8

-

1

88986042

88986123

Intergenic
region

#23

right

8

7

19

57114454

57114530

Ablim1
intronic region

#24

right

8

-

6

10123095

10123157

Intergenic
region

#25

left

7

-

5

32180060

32180151

Intergenic
region

#26

right

6

-

2

74223656

74223761

Intergenic
region

43677099

44995104

Genomic
region

Kynu intronic
region

Ebf1 intronic
region
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Fig. 4 Detection and characterization of RIs and imprecise on-target insertions of the donor DNA in founder
mice. A Location of PCR primers (M389 and M026) in the donor DNA cassette. B PCR screening of insertion
sites for 22 ICSs using the pooled DNA derived from founder mice (P) and wild type (W) as templates. Yellow
arrows indicate the fragments amplified only from founder mice. C PCR screening of the individual founder
mice for eight ICSs detected by PCR in (B). Yellow arrows indicate the fragments uniquely amplified from
founder mice. D Schematic for configuration of the inserted sequence. The junctional sequences of six loci
(from nine ICSs) were analyzed by Sanger sequence. Chromosome positions were obtained from the UCSC
Mouse Genome Browser, mm10 assembly. (CA)19 and (CA)71 indicate the length of 19 and 71 CA repeats,
respectively. Dashed horizontal lines indicate deleted region of the genome. The solid red line indicates the
tandemly duplicated region with mCitrine cassette. The purple line indicates a long terminal repeat (LTR)
region of the endogenous retrovirus (ERVL). N.D., not determined

accompanied by a duplication of an approximately 1.7 kb region adjacent to the insertion site. ICS#7 had an mCitrine cassette insertion, along with 623 bp of a long terminal repeat (LTR) sequence of murine endogenous retrovirus (ERVL). The results of PCR
analysis suggested that the mCitrine cassette was inserted in the intronic region of the
Ablim1 gene in the reverse direction in ICS#23. However, the flanking sequence could
not be determined due to the presence of more than 71 repeated CA repeats immediately downstream of the right arm (Fig. 4D). The CRISPR-KRISPR analysis identified
ICS#10/#15, which is also an identical ICS located close to the on-target site of founder
mouse 11, and the sequence was confirmed up to the middle of the T2A-mCitrine cassette, but the rest of the sequence could not be determined. Further analysis of this
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founder mouse 11 revealed a complex mix of mosaic alleles. In brief, this study could
identify four different alleles, each with imperfections at either or both ends of the insertion sites. The results of this mouse necessitated a separate discussion, which is included
as supplementary text (Additional file 1: Supplemental text). If this mouse were chosen
for breeding to establish germ line transmission, correctly targeted alleles would never
have been found in the F1 offspring because such an allele did not exist in this founder
mouse. The portions of alleles containing correct ends at the junctions perhaps contributed to showing correctly targeted PCR amplicons when standard junctional-PCR genotyping assays were performed.
Characterization of ICSs identified by the CRISPR-KRISPR method

Of the 23 ICSs identified, nine sites (at six different loci as described above) were found
to contain mCitrine cassettes. Of the six loci, two were derived from inaccurate insertions into the target or the close vicinity of the on-target region (ICS#4 and ICS#10/#15),
and the remaining four (ICS#3/#14, ICS#5/#9, ICS#7, and ICS#23) were derived from
randomly inserted cassettes in places unrelated to the on-target region. It is noteworthy
that all these randomly inserted loci were found to be in the intronic region of the gene.
As for the 14 ICSs for which actual insertions could not be confirmed, a possibility of
RI of cassettes cannot be completely ruled out, and it is interesting to note that nine of
them were mapped within introns of known genes. We then examined chromatin accessibility at 23 ICSs using genome-wide DNase I hypersensitive sites (DHSs) data in early
mouse embryonic stages [30] to see if genes in these regions were expressed (in those
embryonic stages) and had open chromatin structures. The results showed no ICSs overlapping with the DHSs in all embryonic stages analyzed, i.e., one-cell, two-cell, four-cell,
eight-cell, and Morula stages (Additional file 1: Fig. S6). We also assessed the expression
profiles of 13 genes in association with 23 ICSs based on RNA-seq data of early mouse
embryos (one-cell, two-cell, and four-cell stages) registered in DBTMEE (http://dbtmee.
hgc.jp/index.php). However, we did not find any association between the gene expression patterns at the one-cell, two-cell, and four-cell stages and ICSs (Additional file 1:
Fig. S7).
Next, we performed Dotplot analysis of the four RI loci (ICS#3/#14, ICS#5/#9, ICS#7,
and ICS#23) to examine if sequence similarity between the surrounding sequences and
the insertion cassettes existed. The analysis was performed using the genomic similarity search tool YASS (https://bioinfo.lifl.fr/yass/yass.php). The results showed that
sequences in the vicinity of two ICSs (ICS#3/#14 and ICS#5/#9) had partial homology to
the mCitrine cassette sequence (Additional file 1: Figs. S8-S9).
Since three of the four insertions (ICS#3/#14, ICS#7, and ICS#23) were detected
within or accompanied by repeat sequences (microsatellite, LTR of ERVL, and microsatellite, respectively, as described above), we hypothesized that the insertions tend to
occur at higher frequencies near the repeat sequences. To verify this, we used Dfam
(https://dfam.org/home) to investigate the presence of repetitive sequences within the
neighboring sequences in all four loci. The results showed that all loci contained one
or more repetitive sequences in the flanking region (around 500 bp) to varying degrees:
ICS#3/#14 was inserted near LTR, short interspersed nuclear element (SINE) and simple repeat sequences (corresponding to 69.0% sequence length), ICS#5/#9 was inserted
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near SINE and Simple repeat sequences (corresponding to 6.5% of the sequence length),
ICS#7 was inserted near SINE and long interspersed nuclear element (LINE) sequences
(corresponding to 24.6% of the sequence length), and ICS#23 was inserted near SINE
sequences (corresponding to 13.1% of the sequence length) (Additional file 1: Figs.
S10-S13). The repeat elements such as LINEs (19.2%), SINEs (8.2%), LTRs (9.9%), and
Simple repeats (2.3%) occupy about 41.2% of the mouse genome [31]. These results suggest that although we noted some RIs were in the repeat sequences, or accompanied by
repeat sequences, in general, it is hard to conclude whether RIs always occur near repeat
sequences. Even if RIs are accompanied by repeat sequences, they are not always in the
regions where repeat sequences are abundant.

Discussion
Modification of the CIRCLE-seq protocol

In this study, we made modifications to the original CIRCLE-seq protocol to identify
OT and RI sites among the CRISPR knock-in mice and we named the method CRISPRKRISPR. One of the drawbacks of CIRCLE-seq is that it requires as much as 25 μg of
DNA. Although we initially used the original protocol, the yield of library DNA was too
low to be used for analysis. Changing the genome fragmentation step to an enzymatic
cleavage method using KAPA HyperPlus increased the yield of library DNA by about
150-fold. This allowed us to perform CIRCLE-seq with an amount of ~3 μg of genomic
DNA; this amount can be easily obtained from tail piece or earpiece DNA isolations.
The CRISPR-KRISPR method also has the advantage that it does not require equipment
for DNA fragmentation. One of the aspects of enzymatic fragmentation approaches is
that they may induce the formation of library molecules containing regions of nearby
DNA from opposite strands (<5%), which may need to be kept in mind during analysis
[32]. Recently, Lazzarotto et al. reported a CHANGE-seq method that can reduce the
amount of DNA required to 5 μg by efficiently generating a circularized library using the
Tn5 transposase. In theory, CHANGE-seq can be potentially used for identification of
RI sites [33].
The OT mutations in the knock-in mice were below the detection limit and were
insignificant, as reported previously in the literature

The OT mutation frequency observed by the targeted deep amplicon sequence was close
to the NGS error rate (~0.1%). Since it is difficult to detect low frequency mutations of
less than 0.1% in amplicon sequencing [34, 35], and since these low frequency mutations have been observed in amplicons of both founder and WT mice, these mutation
candidates are considered to be background noise, such as PCR errors or sequencing
errors. Although the present analysis is based only on an experiment using one gRNA
(Mmp9-Cr1), it suggests that this gRNA is not likely to introduce OT mutations in
mouse embryos. This is consistent with previous reports that OT mutations are seldom
introduced in mouse-embryo injection experiments [15, 16].
CRISPR-KRISPR can be used for identifying (or ruling out) RI sites

The CIRCLE-seq method was originally developed for OT analysis of gRNA cleavage. In
this study, we show that a modified version of CIRCLE-seq (CRISPR-KRISPR) can also
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be used for RI sites of fragments by designing gRNAs in the sequences binding to the
donor DNA. RI analysis by CRISPR-KRISPR can also be used for analyzing founders in
the following types of genome engineering experiments: insertion of tag sequences such
as loxP into the genome, insertion of AAV vectors in gene delivery experiments, and
insertion of donor DNA fragment by newer CRISPR-based methods such as prime editing. The CRISPR-KRISPR method helps identify, or rule out, both OT and RI as a unified
method by using several gRNAs in the experiment: the knock-in gRNA for OT detection
and gRNA(s) binding to the donor DNA for RI detection, respectively. Thus, the method
can be adapted as a standard practice to evaluate founder generation animals prior to
their establishing the germ line-transmitted breeder lines. The CRISPR-KRISPR method
can also be useful for characterizing knock-in loci in other model organisms, including
cell lines [36].
When designing gRNAs for ICS detection, the distance and position from the arm
end of the insertion cassette to the gRNA must be considered, which can be dependent
on the NGS read length. We used an lssDNA knock-in project as a test case to evaluate the CRISPR-KRISPR method because the donor cassette contains shorter homology
arms (about 60 bases long). This knock-in project was amenable for identifying RI events
using a short-read sequencer like MiSeq that reads up to 150 bases. Also, the presence of
repeat sequences such as LINEs in the vicinity of the RI position can also make detection
difficult using the short-read sequencing method. In case of situations like these (donors
that contain longer homology arms or sequences with repeat regions), the MiSeq-based
short-read sequencer approach may not be useful. However, there has been significant
technical advance during the past couple years in long-range sequencing (LRS), which
should be useful in such situations [37]. It is noteworthy that the method to identify RI
sites of transgenes using Nanopore Technologies (called CRISPR-LRS) was developed
recently [38].
We would like to note that CRISPR-KRISPR method can potentially identify partial insertions. It is possible that partial insertions of truncated fragments can occur in
knock-in experiments. Note that we used two guides, one each in the homology arm
regions, and as expected, all the RIs contained the guide binding sites. The CRISPRKRISPR method can possibly be used for identifying partial insertions of different
regions of the insertion cassette if gRNAs binding to different regions throughout the
cassette are included in the assay.
Characteristics of RI sites in the genome-edited mice

The CRISPR-KRISPR approach identified a total of 802 OT cleavage sites and 23 ICSs
(Additional file 1: Fig. S4), but none of the 23 ICSs were in any of the 802 OT sites.
This suggests that the donor DNA fragments were not inserted into the potential OT
sites because of the Cas9 cleavage. In cell culture experiments using reporter cassettes,
it is shown that RIs can occur in knock-in experiments using both ssDNA and dsDNA
donors independent of target homology. Of the two formats of donors, dsDNAs are
thought to have higher RI rates compared to ssDNAs [39], although we have not tested
the RI rates of dsDNA donors using the CRISPR-KRISPR method. Considering that 7
out of 12 mice contained correctly targeted alleles, i.e., a twofold higher rate of correct
insertions (6 out of 11 founders analyzed) compared to RI (3 out of 11), the long ssDNA
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insertion approach is still a highly efficient and reliable method for generating knockin models. It should be noted that it is difficult to conclude typical ranges of RI rates
of donor DNAs by testing only one locus. A systematic approach wherein several loci
(about a dozen or more) tested using different formats of donors such as linear ssDNAs,
circular ssDNA, linear dsDNA, or circular dsDNA need to be analyzed in order to find
out the typical ranges of RI rates of different donor DNA formats.
Our results show that donor DNA insertions occurred at regions where no homology with the donor was found, although some inserted loci had partial homology to
the mCitrine cassette. We also found that DNA donors tend to insert into the intronic
regions and/or repetitive sequence regions. Regarding the RI of dsDNA into the genome,
there are several reports on the insertion tendency. For example, among the transgenic
animal models generated by conventional methods, transgene sequences typically insert
into host gene regions [40], near minisatellite sequences [41], or at repeat elements such
as retrotransposons [42]. It is also reported that insertions can occur in addition to DNA
rearrangement [42]. In the iGUIDE method using dsDNA as a donor, it is reported that
donor DNA is preferentially inserted at spontaneous DSB sites, or close to genes [43]. It
is interesting to note the potential similarity of characteristics of insertion sites between
dsDNA and ssDNA donor formats.
Although RIs would be a major problem in the case of somatic cell gene therapy, in
general, this may not be a significant problem in knock-in animal generation because
extra insertion alleles can be easily eliminated by breeding, except in the cases where the
RI is very close to the on-target correction insertion. In this study, however, we identified that two of four RIs (ICS#3/#14 and ICS#5/#9) were on chromosome 2, which is the
same as the on-target site. The founder mice containing these RIs (founder mice 6 and 7)
also contained correct insertion at the on-target site. We have not determined whether
RI and correct insertion were on the same parental chromosome in cis. The genetic distances between on-target (Mmp9) and ICS#3/#14 (Kynu) or ICS#5/#9 (Col5a1) were far
enough (59.6 cM between Mmp9 and Kynu, 65.9 cM between Mmp9 and Col5a1) to get
the respective on-target KI and RI mutations segregated by breeding. If such cis insertions are close to each other, breeding to segregate them may not be possible. Collectively, our observations suggest that it is important to identify founder mice that contain
RIs in order to rule out lesions that are unidentifiable using standard genotyping PCRs
with primers that bind to the insertional junctions [44]. Therefore, CRISPR-KRISPR can
help confirm the correct on-target insertions, on-target imprecise insertions, and also
rule out/identify other RIs. Once RIs are identified among the correctly targeted founders, genotyping PCRs to identify those RIs can be developed, and RI specific genotyping
is required not only on the founder animals but also on the next-generation offspring to
exclude the ones that contain RIs for further breeding. Since mosaicism in founders is
one of the common problems among the CRISPR genome edited mice [45, 46], it would
be necessary to confirm correct insertions in F1 mice and to ensure that the integrated
sequence is a single copy in the genome by qPCR or ddPCR.
The scientific community is well aware that genotyping to identify correctly targeted
animals among the CRISPR genome edited animals is not straightforward because
of mosaicism and because the DNA repair outcomes at the CRISPR cleaved genomic
sites are unpredictable. Several types of genomic rearrangements, including insertion
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of fragments of DNA from other genomic regions or fragments of retrotranscribed
sequences can occur [47]. Even though standard junctional PCRs, used for genotyping founder animals, can indicate that an animal is correctly targeted, such results can
be deceiving sometimes. Additional assays (like the one described in this study) can
uncover the hidden complex genomic rearrangements. An example is founder mouse
11, which contained a mixture of four different incorrectly targeted alleles, yet the two
junctional PCRs showed correct targeting because the two PCRs identified the correct
amplicons, perhaps from the templates derived from different alleles. While this was the
case with just one of six founders in this example, it would be prudent to ensure that
the founder animal(s) chosen for further breeding indeed are accurately targeted and are
devoid of OTs and RIs by analyzing them with an assay like CRISPR-KRISPR.

Conclusions
The CRISPR-KRISPR method (a modified version of the CIRCLE-seq) requires only ~3
μg gDNA to generate a circularized DNA library, successfully identifying RI sites in the
CRISPR knock-in mice. RI regions identified indicated that the DNA donor templates
have a tendency to insert in the intronic regions, accompanied by genomic deletions or
duplications, and/or with repeat elements. The CRISPR-KRISPR method can be adapted
as a standard protocol to evaluate founder generation animals to choose the ones that do
not have OTs or RIs for further breeding.

Methods
Genomic DNA

C57BL/6J mice and 11 founder mice obtained by Easi-CRISPR using a repair template
containing the T2A-mCitrine cassette were used for CRISPR-KRISPR experiments [6].
Genomic DNAs were extracted from these mouse tails using the DNeasy Blood & Tissue
Kit (Qiagen).

CRISPR guide RNAs design

For screening in vivo OCS, we used the guide RNA (gRNA) for Mmp9 (Mmp9-Cr1)
(Additional file 1: Fig. S1A and Table S1) [6]. For detection of ICS in founder mice,
we designed two gRNAs (named as gRNA-L and gRNA-R) by using CHOPCHOP [19]
and CRISPR-direct [48] (Additional file 1: Table S1). Each gRNA was located in the left
arm and right arm of the Mmp9-T2A-mCitrine cassette, respectively (Additional file 1:
Fig. S3A).

CIRCLE-seq library preparation

We prepared the CIRCLE-seq library according to the previously described protocol [24], with slight modification. Briefly, purified genomic DNA was sheared with the
KAPA Hyper plus kit (Kapa Biosystems) to an average length of 300 bp. The fragmented
DNA was end-repaired, A-tailed, and ligated to an uracil-containing stem-loop adaptor oSQT1288 5′-P-CGGTGGACCGATGATCUATCGGTCCACCG*T-3′, where “*”

Page 14 of 19

Tanaka et al. Genome Biology

(2022) 23:228

indicates phosphorothioate linkage. Adapter-ligated DNA molecules were then selected
by eliminating molecules that did not have adaptors ligated to both ends using a mixture of Lambda Exonuclease (NEB) and E. coli Exonuclease I (NEB). Adapter-ligated
DNA was then treated with USER enzyme (NEB) and T4 polynucleotide kinase (NEB)
to expose and add 5′ phosphorylation of cohesive ends. DNA was circularized at 5 ng/
μl concentration using T4 DNA ligase and treated with Plasmid-Safe ATP-dependent
DNase (Epicentre) to degrade unligated linear DNA molecules. In vitro cleavage reactions were performed in a 100 μl volume with 1 x NEB 3 buffer (NEB), 90 nM SpCas9
protein (Integrated DNA Technologies), 90 nM gRNA, and 250 ng of circularized and
Plasmid Safe-treated DNA. Digested products were A-tailed, ligated with a hairpin adaptor (NEBNext Multiplex Oligos for Illumina (NEB)), treated with USER enzyme (NEB),
and amplified by PCR using Kapa HiFi polymerase (Kapa Biosystems). Completed libraries were quantified by qPCR using KAPA Library Quantification Kits (NIPPON Genetics Co, Ltd). The average length of libraries was calculated as 450 bp (average length of
seared genome 300 bp + hairpin adaptor 30 bp + sequence adaptor 120 bp). Sequencing
was performed using a MiSeq V2 reagent kit (150 bp paired end reads) on an Illumina
MiSeq instrument. For identification of OCS, the library treated with Mmp9-Cr1 was
sequenced 2 million reads. For identification of ICS, the libraries treated with gRNA-L
and gRNA-R were sequenced 10 million and 13 million reads, respectively.
CIRCLE-seq data analysis

To identify OCSs, the CIRCLE-seq data were processed using v.1.1 of the CIRCLEseq open-source analysis software with the following parameters: “read_threshold: 4;
window_size: 3; mapq_threshold: 50; start_threshold: 1; gap_threshold: 3; mismatch_
threshold: 6; merged_analysis: True.” In this analysis, targeted sequences containing
insertions (DNA bulge), or deletions (RNA bulge) compared to the gRNA strand, and
non-canonical PAM for SpCas9 (such as NGA and NAG) were considered [49, 50]. The
CIRCLE-seq data processing procedure for ICSs identification is illustrated in Additional file 1: Fig. S14: (1) CIRCLE-seq reads were processed by circleseq-tools with the
reference-genome-independent module to identify Cas9 cleavage sites. (2) The identified reads were mapped to a T2A-mCitrine cassette sequence by BLAST search with
e-value threshold of 1e-10 in the founder mice library. (3) After filtering, the remaining
reads were mapped to mouse genome (mm10) by BLAST search with e-value threshold
of 1e−10. (4) Mapped regions with less than five reads were eliminated. (5) The remaining mapped regions were manually checked by the Integrative Genomics Viewer (IGV),
and the regions that passed all the filters were regarded as ICSs.
In silico screening of potential OT sites

The Cas-OFFinder tool [18] was used to find all OCSs based on sequence homology
to the Mmp9-Cr1, gRNA-L, and gRNA-R with the following parameters: allowing up
to six mismatches, DNA bulge size less than 2, RNA bulge size less than 2, and noncanonical PAMs. Then, we filtered the predicted sites either equal to six mismatches
in the spacer or up to two mismatches in the canonical NGG PAM.
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Targeted amplicon sequencing for OCS analysis

The primer pairs for OCS amplicon sequencing were designed using Primer3 web
tools (Additional file 1: Table S3). Amplicons were amplified with KOD Fx DNA
polymerase (Toyobo) or PrimeSTAR GXL DNA polymerase (TaKaRa) using 25 ng
genomic DNA as a template. Amplicons from each mouse are mixed in equal amount,
purified using AMPure XP beads (Beckman Coulter), and quantified by Qubit dsDNA
High-Sensitivity kit (Thermo Fisher Scientific). The amplicon mixtures were endrepaired and A-tailed using the KAPA LTP Library Preparation Kit (Kapa Biosystems).
Adapters for sequencing were ligated to A-tailed samples and purified by AMPure
XP beads. A 13 pM sequence library solution was loaded onto the Illumina MiSeq
flow cell. All amplicons were sequenced (more than 2,000 reads/amplicon: mean read
coverage = 17,884 reads). Analysis of amplicon sequencing was performed using
CRISPResso software v0.1.0 [51] with the following parameters: “-q 30 --ignore_substitutions --hide_mutations_outside_window_NHEJ --min_reads_to_use_region 100.”
On-target primer pair for PCR and Sanger sequencing was previously described [6].
On-target amplicons were confirmed by Sanger sequencing.
In vitro Cas9 digestion of OCS amplicons

OCS amplicons were prepared using the same conditions as targeted amplicon
sequencing. A 20 μl solution containing 10 x NEB 3 buffer (NEB), Alt-R® S.p. Cas9
Nuclease (Integrated DNA Technologies), and gRNA mixture was incubated for 10
min at room temperature. Seventeen nanograms of PCR amplicon was added into this
mixture and incubated for 30 min at 37 °C. Final concentration of SpCas9 and gRNA
were adjusted to 100 nM. Confirmation of DNA cleavage was performed using an
Agilent 2100 Bioanalyzer (Agilent Technologies) with High Sensitivity DNA Kit.
ICS analyses

ICS primers were designed to amplify either entire ICS regions or junctional regions
between the ICS and T2A-mCitrine cassette (Additional file 1: Table S4). Genomic DNA
isolated from 11 founder mice were pooled in equal amount and diluted to 20 ng/μl
concentration. Twenty microliters of standard reaction mixture for KOD FX Neo (Toyobo) was used for amplification of ICS regions with 20 ng genomic DNA as a template
(pooled genomic DNA from founder mice and control genomic DNA from a wildtype
mouse). PCR was performed with a denaturation step at 94oC for 2 min, followed by 30
cycles of 98 °C for 10 s, 60 °C for 30 s, and 68 °C for 1 min. Amplifications of PCR fragments were checked by 1% agarose-gel electrophoresis.
Quantitative PCR analysis

To determine the copy number of the mCitrine cassette in the genomes of each founder
mouse, we used primers to amplify a part of the mCitrine cassette (PP341: 5′-GGGTGC
CCATCCTGGTCGA-3′, PP267: 5′-AGCTTGCCGTAGGTGGCATC-3′). ActB primer
set was used as a normalization control (ActB-forward: 5′-CATGAAGTGTGACGT
TGACATC-3, ActB-reverse: 5′-ATGATCTTGATCTTCATGGTGC-3′). For each sample, dilution series were made to 20 ng, 10 ng, 5 ng, 2.5 ng, 1.25 ng, 0.625 ng, and 0.3125
ng/well of DNA, then mixed with Fast SYBR® Green Master Mix (2×) (Thermo Fisher
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Scientific) and primers (0.5 ng in reaction solution). Each sample was analyzed using
Quantstudio 3 (Thermo Fisher Scientific). Amplification conditions were 20 s at 95 °C,
1 s at 95 °C, and 20 s at 60 °C for 40 cycles. Data analysis was performed with the Quant
Studio Design & Analysis Software v1.5.1. The threshold for all samples was set at 0.1,
and a calibration curve was generated for all samples. After performing normalization
with ActB, the copy number of each sample was calculated by comparing it to an eGFP
transgenic mouse (the copy number was set to 2 because a homozygous individual was
used) having the same sequence as the part of mCitrine.
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